##gff-version 3								
##gvf-version 1.10								
##species https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049								
#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
NC_045512.2	.	snp	210	210	.	+	.	ID=ID_0;Name=g.G-56T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G-56T;aa_name=;hgvs_nt=NC_045512.2:g.56G>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	241	241	.	+	.	ID=ID_1;Name=g.C-25T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C-25T;aa_name=;hgvs_nt=NC_045512.2:g.25C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	335	335	.	+	.	ID=ID_2;Name=R24C;alias=R24C;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=443;ao=7;dp=450;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C70T;aa_name=p.R24C;hgvs_nt=NC_045512.2:g.70C>T;hgvs_aa=YP_009724389.1:p.Arg24Cys;hgvs_alias=YP_009724389.1:Arg24Cys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.015555555555555555;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	835	835	.	+	.	ID=ID_3;Name=F190F;alias=F10F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=441;ao=9;dp=450;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C570T;aa_name=p.F190F;hgvs_nt=NC_045512.2:g.570C>T;hgvs_aa=YP_009724389.1:p.Phe190Phe;hgvs_alias=YP_009724389.1:Phe10Phe;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1126	1126	.	+	.	ID=ID_4;Name=R287S;alias=R107S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=446;ao=4;dp=450;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G861T;aa_name=p.R287S;hgvs_nt=NC_045512.2:g.861G>T;hgvs_aa=YP_009724389.1:p.Arg287Ser;hgvs_alias=YP_009724389.1:Arg107Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008888888888888889;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1585	1585	.	+	.	ID=ID_5;Name=G440G;alias=G260G;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=447;ao=3;dp=450;sample_size=472;Reference_seq=A;Variant_seq=C;nt_name=g.A1320C;aa_name=p.G440G;hgvs_nt=NC_045512.2:g.1320A>C;hgvs_aa=YP_009724389.1:p.Gly440Gly;hgvs_alias=YP_009724389.1:Gly260Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2144	2144	.	+	.	ID=ID_6;Name=V627F;alias=V447F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=443;ao=7;dp=450;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G1879T;aa_name=p.V627F;hgvs_nt=NC_045512.2:g.1879G>T;hgvs_aa=YP_009724389.1:p.Val627Phe;hgvs_alias=YP_009724389.1:Val447Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.015555555555555555;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2334	2334	.	+	.	ID=ID_7;Name=A690V;alias=A510V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C2069T;aa_name=p.A690V;hgvs_nt=NC_045512.2:g.2069C>T;hgvs_aa=YP_009724389.1:p.Ala690Val;hgvs_alias=YP_009724389.1:Ala510Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2485	2485	.	+	.	ID=ID_8;Name=I740I;alias=I560I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=442;ao=9;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C2220T;aa_name=p.I740I;hgvs_nt=NC_045512.2:g.2220C>T;hgvs_aa=YP_009724389.1:p.Ile740Ile;hgvs_alias=YP_009724389.1:Ile560Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.019955654101995565;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3037	3037	.	+	.	ID=ID_9;Name=F924F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C2772T;aa_name=p.F924F;hgvs_nt=NC_045512.2:g.2772C>T;hgvs_aa=YP_009724389.1:p.Phe924Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3457	3457	.	+	.	ID=ID_10;Name=Y1064Y;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C3192T;aa_name=p.Y1064Y;hgvs_nt=NC_045512.2:g.3192C>T;hgvs_aa=YP_009724389.1:p.Tyr1064Tyr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3805	3805	.	+	.	ID=ID_11;Name=K1180K;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A3540G;aa_name=p.K1180K;hgvs_nt=NC_045512.2:g.3540A>G;hgvs_aa=YP_009724389.1:p.Lys1180Lys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4285	4285	.	+	.	ID=ID_12;Name=E1340D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G4020T;aa_name=p.E1340D;hgvs_nt=NC_045512.2:g.4020G>T;hgvs_aa=YP_009724389.1:p.Glu1340Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4965	4965	.	+	.	ID=ID_13;Name=T1567I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C4700T;aa_name=p.T1567I;hgvs_nt=NC_045512.2:g.4700C>T;hgvs_aa=YP_009724389.1:p.Thr1567Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5309	5309	.	+	.	ID=ID_14;Name=T1682A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=440;ao=11;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A5044G;aa_name=p.T1682A;hgvs_nt=NC_045512.2:g.5044A>G;hgvs_aa=YP_009724389.1:p.Thr1682Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024390243902439025;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6429	6429	.	+	.	ID=ID_15;Name=P2055L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=435;ao=16;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C6164T;aa_name=p.P2055L;hgvs_nt=NC_045512.2:g.6164C>T;hgvs_aa=YP_009724389.1:p.Pro2055Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03547671840354767;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6532	6532	.	+	.	ID=ID_16;Name=E2089D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=141;ao=310;dp=451;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G6267T;aa_name=p.E2089D;hgvs_nt=NC_045512.2:g.6267G>T;hgvs_aa=YP_009724389.1:p.Glu2089Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6873614190687362;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7633	7633	.	+	.	ID=ID_17;Name=D2456D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=T;Variant_seq=C;nt_name=g.T7368C;aa_name=p.D2456D;hgvs_nt=NC_045512.2:g.7368T>C;hgvs_aa=YP_009724389.1:p.Asp2456Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	8491	8491	.	+	.	ID=ID_18;Name=L2742L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=85;ao=366;dp=451;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G8226A;aa_name=p.L2742L;hgvs_nt=NC_045512.2:g.8226G>A;hgvs_aa=YP_009724389.1:p.Leu2742Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.811529933481153;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	8733	8733	.	+	.	ID=ID_19;Name=T2823I;alias=T60I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=447;ao=3;dp=450;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C8468T;aa_name=p.T2823I;hgvs_nt=NC_045512.2:g.8468C>T;hgvs_aa=YP_009724389.1:p.Thr2823Ile;hgvs_alias=YP_009724389.1:Thr60Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	8802	8802	.	+	.	ID=ID_20;Name=T2846I;alias=T83I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=437;ao=13;dp=450;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C8537T;aa_name=p.T2846I;hgvs_nt=NC_045512.2:g.8537C>T;hgvs_aa=YP_009724389.1:p.Thr2846Ile;hgvs_alias=YP_009724389.1:Thr83Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.028888888888888888;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9130	9130	.	+	.	ID=ID_21;Name=V2955V;alias=V192V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G8865T;aa_name=p.V2955V;hgvs_nt=NC_045512.2:g.8865G>T;hgvs_aa=YP_009724389.1:p.Val2955Val;hgvs_alias=YP_009724389.1:Val192Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10633	10633	.	+	.	ID=ID_22;Name=A3456A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A10368G;aa_name=p.A3456A;hgvs_nt=NC_045512.2:g.10368A>G;hgvs_aa=YP_009724389.1:p.Ala3456Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11003	11003	.	+	.	ID=ID_23;Name=H3580Y;alias=H11Y;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=447;ao=3;dp=450;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C10738T;aa_name=p.H3580Y;hgvs_nt=NC_045512.2:g.10738C>T;hgvs_aa=YP_009724389.1:p.His3580Tyr;hgvs_alias=YP_009724389.1:His11Tyr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11083	11083	.	+	.	ID=ID_24;Name=L3606F;alias=L37F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G10818T;aa_name=p.L3606F;hgvs_nt=NC_045512.2:g.10818G>T;hgvs_aa=YP_009724389.1:p.Leu3606Phe;hgvs_alias=YP_009724389.1:Leu37Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11201	11201	.	+	.	ID=ID_25;Name=T3646A;alias=T77A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A10936G;aa_name=p.T3646A;hgvs_nt=NC_045512.2:g.10936A>G;hgvs_aa=YP_009724389.1:p.Thr3646Ala;hgvs_alias=YP_009724389.1:Thr77Ala;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11812	11812	.	+	.	ID=ID_26;Name=G3849G;alias=G280G;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=441;ao=10;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C11547T;aa_name=p.G3849G;hgvs_nt=NC_045512.2:g.11547C>T;hgvs_aa=YP_009724389.1:p.Gly3849Gly;hgvs_alias=YP_009724389.1:Gly280Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.022172949002217297;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12202	12202	.	+	.	ID=ID_27;Name=K3979N;alias=K37N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G11937T;aa_name=p.K3979N;hgvs_nt=NC_045512.2:g.11937G>T;hgvs_aa=YP_009724389.1:p.Lys3979Asn;hgvs_alias=YP_009724389.1:Lys37Asn;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12400	12400	.	+	.	ID=ID_28;Name=L4045L;alias=L103L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C12135T;aa_name=p.L4045L;hgvs_nt=NC_045512.2:g.12135C>T;hgvs_aa=YP_009724389.1:p.Leu4045Leu;hgvs_alias=YP_009724389.1:Leu103Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14408	14408	.	+	.	ID=ID_29;Name=P4715L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C14144T;aa_name=p.P4715L;hgvs_nt=NC_045512.2:g.14144C>T;hgvs_aa=YP_009724389.1:p.Pro4715Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14874	14874	.	+	.	ID=ID_30;Name=K4870N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=428;ao=23;dp=451;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G14610T;aa_name=p.K4870N;hgvs_nt=NC_045512.2:g.14610G>T;hgvs_aa=YP_009724389.1:p.Lys4870Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.050997782705099776;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	15646	15646	.	+	.	ID=ID_31;Name=D5128N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=445;ao=6;dp=451;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G15382A;aa_name=p.D5128N;hgvs_nt=NC_045512.2:g.15382G>A;hgvs_aa=YP_009724389.1:p.Asp5128Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013303769401330377;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16134	16134	.	+	.	ID=ID_32;Name=H5290H;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=84;ao=366;dp=450;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C15870T;aa_name=p.H5290H;hgvs_nt=NC_045512.2:g.15870C>T;hgvs_aa=YP_009724389.1:p.His5290His;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8133333333333334;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16405	16405	.	+	.	ID=ID_33;Name=V5381F;alias=V57F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=446;ao=3;dp=449;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G16141T;aa_name=p.V5381F;hgvs_nt=NC_045512.2:g.16141G>T;hgvs_aa=YP_009724389.1:p.Val5381Phe;hgvs_alias=YP_009724389.1:Val57Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066815144766146995;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16575	16575	.	+	.	ID=ID_34;Name=D5437D;alias=D113D;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=446;ao=4;dp=450;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C16311T;aa_name=p.D5437D;hgvs_nt=NC_045512.2:g.16311C>T;hgvs_aa=YP_009724389.1:p.Asp5437Asp;hgvs_alias=YP_009724389.1:Asp113Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008888888888888889;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16852	16852	.	+	.	ID=ID_35;Name=G5530C;alias=G206C;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G16588T;aa_name=p.G5530C;hgvs_nt=NC_045512.2:g.16588G>T;hgvs_aa=YP_009724389.1:p.Gly5530Cys;hgvs_alias=YP_009724389.1:Gly206Cys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16877	16877	.	+	.	ID=ID_36;Name=T5538I;alias=T214I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=447;ao=4;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C16613T;aa_name=p.T5538I;hgvs_nt=NC_045512.2:g.16613C>T;hgvs_aa=YP_009724389.1:p.Thr5538Ile;hgvs_alias=YP_009724389.1:Thr214Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008869179600886918;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16917	16917	.	+	.	ID=ID_37;Name=L5551L;alias=L227L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G16653T;aa_name=p.L5551L;hgvs_nt=NC_045512.2:g.16653G>T;hgvs_aa=YP_009724389.1:p.Leu5551Leu;hgvs_alias=YP_009724389.1:Leu227Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17002	17002	.	+	.	ID=ID_38;Name=L5580F;alias=L256F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=199;ao=252;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C16738T;aa_name=p.L5580F;hgvs_nt=NC_045512.2:g.16738C>T;hgvs_aa=YP_009724389.1:p.Leu5580Phe;hgvs_alias=YP_009724389.1:Leu256Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5587583148558758;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17338	17338	.	+	.	ID=ID_39;Name=A5692S;alias=A368S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=86;ao=365;dp=451;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G17074T;aa_name=p.A5692S;hgvs_nt=NC_045512.2:g.17074G>T;hgvs_aa=YP_009724389.1:p.Ala5692Ser;hgvs_alias=YP_009724389.1:Ala368Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8093126385809313;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17523	17523	.	+	.	ID=ID_40;Name=M5753I;alias=M429I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G17259T;aa_name=p.M5753I;hgvs_nt=NC_045512.2:g.17259G>T;hgvs_aa=YP_009724389.1:p.Met5753Ile;hgvs_alias=YP_009724389.1:Met429Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17528	17528	.	+	.	ID=ID_41;Name=T5755I;alias=T431I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=447;ao=4;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C17264T;aa_name=p.T5755I;hgvs_nt=NC_045512.2:g.17264C>T;hgvs_aa=YP_009724389.1:p.Thr5755Ile;hgvs_alias=YP_009724389.1:Thr431Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008869179600886918;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17977	17977	.	+	.	ID=ID_42;Name=L5905F;alias=L581F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C17713T;aa_name=p.L5905F;hgvs_nt=NC_045512.2:g.17713C>T;hgvs_aa=YP_009724389.1:p.Leu5905Phe;hgvs_alias=YP_009724389.1:Leu581Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	18100	18100	.	+	.	ID=ID_43;Name=T5946A;alias=T21A;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=441;ao=10;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A17836G;aa_name=p.T5946A;hgvs_nt=NC_045512.2:g.17836A>G;hgvs_aa=YP_009724389.1:p.Thr5946Ala;hgvs_alias=YP_009724389.1:Thr21Ala;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.022172949002217297;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	18744	18744	.	+	.	ID=ID_44;Name=Y6160Y;alias=Y235Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=441;ao=10;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C18480T;aa_name=p.Y6160Y;hgvs_nt=NC_045512.2:g.18480C>T;hgvs_aa=YP_009724389.1:p.Tyr6160Tyr;hgvs_alias=YP_009724389.1:Tyr235Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.022172949002217297;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	18984	18984	.	+	.	ID=ID_45;Name=M6240I;alias=M315I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=439;ao=12;dp=451;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G18720T;aa_name=p.M6240I;hgvs_nt=NC_045512.2:g.18720G>T;hgvs_aa=YP_009724389.1:p.Met6240Ile;hgvs_alias=YP_009724389.1:Met315Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.026607538802660754;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19145	19145	.	+	.	ID=ID_46;Name=S6294F;alias=S369F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=446;ao=5;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C18881T;aa_name=p.S6294F;hgvs_nt=NC_045512.2:g.18881C>T;hgvs_aa=YP_009724389.1:p.Ser6294Phe;hgvs_alias=YP_009724389.1:Ser369Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011086474501108648;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19150	19150	.	+	.	ID=ID_47;Name=A6296T;alias=A371T;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G18886A;aa_name=p.A6296T;hgvs_nt=NC_045512.2:g.18886G>A;hgvs_aa=YP_009724389.1:p.Ala6296Thr;hgvs_alias=YP_009724389.1:Ala371Thr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19213	19213	.	+	.	ID=ID_48;Name=Y6317H;alias=Y392H;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=447;ao=4;dp=451;sample_size=472;Reference_seq=T;Variant_seq=C;nt_name=g.T18949C;aa_name=p.Y6317H;hgvs_nt=NC_045512.2:g.18949T>C;hgvs_aa=YP_009724389.1:p.Tyr6317His;hgvs_alias=YP_009724389.1:Tyr392His;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008869179600886918;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19813	19813	.	+	.	ID=ID_49;Name=P6517S;alias=P65S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=437;ao=14;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C19549T;aa_name=p.P6517S;hgvs_nt=NC_045512.2:g.19549C>T;hgvs_aa=YP_009724389.1:p.Pro6517Ser;hgvs_alias=YP_009724389.1:Pro65Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.031042128603104215;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20333	20333	.	+	.	ID=ID_50;Name=G6690E;alias=G238E;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=433;ao=16;dp=449;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G20069A;aa_name=p.G6690E;hgvs_nt=NC_045512.2:g.20069G>A;hgvs_aa=YP_009724389.1:p.Gly6690Glu;hgvs_alias=YP_009724389.1:Gly238Glu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.035634743875278395;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20383	20383	.	+	.	ID=ID_51;Name=A6707S;alias=A255S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G20119T;aa_name=p.A6707S;hgvs_nt=NC_045512.2:g.20119G>T;hgvs_aa=YP_009724389.1:p.Ala6707Ser;hgvs_alias=YP_009724389.1:Ala255Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20396	20396	.	+	.	ID=ID_52;Name=K6711R;alias=K259R;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=1;ao=450;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A20132G;aa_name=p.K6711R;hgvs_nt=NC_045512.2:g.20132A>G;hgvs_aa=YP_009724389.1:p.Lys6711Arg;hgvs_alias=YP_009724389.1:Lys259Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9977827050997783;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20401	20401	.	+	.	ID=ID_53;Name=S6713A;alias=S261A;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T20137G;aa_name=p.S6713A;hgvs_nt=NC_045512.2:g.20137T>G;hgvs_aa=YP_009724389.1:p.Ser6713Ala;hgvs_alias=YP_009724389.1:Ser261Ala;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21588	21588	.	+	.	ID=ID_54;Name=P9L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=444;ao=6;dp=450;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C26T;aa_name=p.P9L;hgvs_nt=NC_045512.2:g.26C>T;hgvs_aa=YP_009724390.1:p.Pro9Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013333333333333334;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21644	21644	.	+	.	ID=ID_55;Name=Y28H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=446;ao=4;dp=450;sample_size=472;Reference_seq=T;Variant_seq=C;nt_name=g.T82C;aa_name=p.Y28H;hgvs_nt=NC_045512.2:g.82T>C;hgvs_aa=YP_009724390.1:p.Tyr28His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008888888888888889;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21751	21751	.	+	.	ID=ID_56;Name=T63T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=391;ao=46;dp=437;sample_size=472;Reference_seq=T;Variant_seq=A;nt_name=g.T189A;aa_name=p.T63T;hgvs_nt=NC_045512.2:g.189T>A;hgvs_aa=YP_009724390.1:p.Thr63Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.10526315789473684;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21846	21846	.	+	.	ID=ID_57;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=437;dp=437;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21846	21846	.	+	.	ID=ID_57;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=437;dp=437;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21846	21846	.	+	.	"ID=ID_58;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=437;dp=437;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,D614G,P681R,Q1071H;function_description=Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21846	21846	.	+	.	ID=ID_57;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=437;dp=437;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21895	21895	.	+	.	ID=ID_59;Name=D111D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=435;dp=435;sample_size=472;Reference_seq=T;Variant_seq=C;nt_name=g.T333C;aa_name=p.D111D;hgvs_nt=NC_045512.2:g.333T>C;hgvs_aa=YP_009724390.1:p.Asp111Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21987	21987	.	+	.	"ID=ID_60;Name=G142D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=428;dp=428;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G425A;aa_name=p.G142D;hgvs_nt=NC_045512.2:g.425G>A;hgvs_aa=YP_009724390.1:p.Gly142Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E154K,L452R,E484Q,D614G,P681R,Q1071H;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as ""not significant"". [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21987	21987	.	+	.	ID=ID_60;Name=G142D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=428;dp=428;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G425A;aa_name=p.G142D;hgvs_nt=NC_045512.2:g.425G>A;hgvs_aa=YP_009724390.1:p.Gly142Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=E154K,L452R,E484Q,D614G,P681R,Q1071H;function_description=~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21987	21987	.	+	.	ID=ID_60;Name=G142D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=428;dp=428;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G425A;aa_name=p.G142D;hgvs_nt=NC_045512.2:g.425G>A;hgvs_aa=YP_009724390.1:p.Gly142Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=E154K,L452R,E484Q,D614G,P681R,Q1071H;function_description=Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21987	21987	.	+	.	ID=ID_60;Name=G142D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=428;dp=428;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G425A;aa_name=p.G142D;hgvs_nt=NC_045512.2:g.425G>A;hgvs_aa=YP_009724390.1:p.Gly142Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=E154K,L452R,E484Q,D614G,P681R,Q1071H;function_description=Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21987	21987	.	+	.	"ID=ID_58;Name=G142D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=428;dp=428;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G425A;aa_name=p.G142D;hgvs_nt=NC_045512.2:g.425G>A;hgvs_aa=YP_009724390.1:p.Gly142Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=T95I,E154K,L452R,E484Q,D614G,P681R,Q1071H;function_description=Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21987	21987	.	+	.	ID=ID_60;Name=G142D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=428;dp=428;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G425A;aa_name=p.G142D;hgvs_nt=NC_045512.2:g.425G>A;hgvs_aa=YP_009724390.1:p.Gly142Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=E154K,L452R,E484Q,D614G,P681R,Q1071H;function_description=Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21987	21987	.	+	.	ID=ID_60;Name=G142D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=428;dp=428;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G425A;aa_name=p.G142D;hgvs_nt=NC_045512.2:g.425G>A;hgvs_aa=YP_009724390.1:p.Gly142Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E154K,L452R,E484Q,D614G,P681R,Q1071H;function_description=1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21987	21987	.	+	.	ID=ID_60;Name=G142D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=428;dp=428;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G425A;aa_name=p.G142D;hgvs_nt=NC_045512.2:g.425G>A;hgvs_aa=YP_009724390.1:p.Gly142Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.23.441101v1;citation=Yadav et al. (2021);comb_mutation=E154K,L452R,E484Q,D614G,P681R,Q1071H;function_description=Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21987	21987	.	+	.	ID=ID_61;Name=G142D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=428;dp=428;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G425A;aa_name=p.G142D;hgvs_nt=NC_045512.2:g.425G>A;hgvs_aa=YP_009724390.1:p.Gly142Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X28, S2X333;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21987	21987	.	+	.	ID=ID_61;Name=G142D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=428;dp=428;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G425A;aa_name=p.G142D;hgvs_nt=NC_045512.2:g.425G>A;hgvs_aa=YP_009724390.1:p.Gly142Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1;citation=Suryadevara et al. (2021);comb_mutation=;function_description=Selected twice in passage with mAb COV2-2489.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22022	22022	.	+	.	"ID=ID_60;Name=E154K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=438;dp=438;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G460A;aa_name=p.E154K;hgvs_nt=NC_045512.2:g.460G>A;hgvs_aa=YP_009724390.1:p.Glu154Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=G142D,L452R,E484Q,D614G,P681R,Q1071H;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as ""not significant"". [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22022	22022	.	+	.	ID=ID_60;Name=E154K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=438;dp=438;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G460A;aa_name=p.E154K;hgvs_nt=NC_045512.2:g.460G>A;hgvs_aa=YP_009724390.1:p.Glu154Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=G142D,L452R,E484Q,D614G,P681R,Q1071H;function_description=~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22022	22022	.	+	.	ID=ID_60;Name=E154K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=438;dp=438;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G460A;aa_name=p.E154K;hgvs_nt=NC_045512.2:g.460G>A;hgvs_aa=YP_009724390.1:p.Glu154Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=G142D,L452R,E484Q,D614G,P681R,Q1071H;function_description=Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22022	22022	.	+	.	ID=ID_62;Name=E154K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=438;dp=438;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G460A;aa_name=p.E154K;hgvs_nt=NC_045512.2:g.460G>A;hgvs_aa=YP_009724390.1:p.Glu154Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1;citation=Schmidt et al. (2021);comb_mutation=;function_description=Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22022	22022	.	+	.	ID=ID_60;Name=E154K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=438;dp=438;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G460A;aa_name=p.E154K;hgvs_nt=NC_045512.2:g.460G>A;hgvs_aa=YP_009724390.1:p.Glu154Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=G142D,L452R,E484Q,D614G,P681R,Q1071H;function_description=Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22022	22022	.	+	.	"ID=ID_58;Name=E154K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=438;dp=438;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G460A;aa_name=p.E154K;hgvs_nt=NC_045512.2:g.460G>A;hgvs_aa=YP_009724390.1:p.Glu154Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=T95I,G142D,L452R,E484Q,D614G,P681R,Q1071H;function_description=Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22022	22022	.	+	.	ID=ID_60;Name=E154K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=438;dp=438;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G460A;aa_name=p.E154K;hgvs_nt=NC_045512.2:g.460G>A;hgvs_aa=YP_009724390.1:p.Glu154Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=G142D,L452R,E484Q,D614G,P681R,Q1071H;function_description=Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22022	22022	.	+	.	ID=ID_60;Name=E154K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=438;dp=438;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G460A;aa_name=p.E154K;hgvs_nt=NC_045512.2:g.460G>A;hgvs_aa=YP_009724390.1:p.Glu154Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=G142D,L452R,E484Q,D614G,P681R,Q1071H;function_description=1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22022	22022	.	+	.	ID=ID_60;Name=E154K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=438;dp=438;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G460A;aa_name=p.E154K;hgvs_nt=NC_045512.2:g.460G>A;hgvs_aa=YP_009724390.1:p.Glu154Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.23.441101v1;citation=Yadav et al. (2021);comb_mutation=G142D,L452R,E484Q,D614G,P681R,Q1071H;function_description=Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22894	22894	.	+	.	ID=ID_63;Name=K444N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=444;ao=5;dp=449;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G1332T;aa_name=p.K444N;hgvs_nt=NC_045512.2:g.1332G>T;hgvs_aa=YP_009724390.1:p.Lys444Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011135857461024499;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22894	22894	.	+	.	ID=ID_63;Name=K444N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=444;ao=5;dp=449;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G1332T;aa_name=p.K444N;hgvs_nt=NC_045512.2:g.1332G>T;hgvs_aa=YP_009724390.1:p.Lys444Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011135857461024499;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22894	22894	.	+	.	ID=ID_63;Name=K444N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=444;ao=5;dp=449;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G1332T;aa_name=p.K444N;hgvs_nt=NC_045512.2:g.1332G>T;hgvs_aa=YP_009724390.1:p.Lys444Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011135857461024499;function_category=antibody epitope effects;source=https://science.sciencemag.org/content/371/6531/823;citation=Rappazzo et al. (2021);comb_mutation=;function_description=Abolishes binding efficiency vs wild type for mAb REGN10933.;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22894	22894	.	+	.	ID=ID_63;Name=K444N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=444;ao=5;dp=449;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G1332T;aa_name=p.K444N;hgvs_nt=NC_045512.2:g.1332G>T;hgvs_aa=YP_009724390.1:p.Lys444Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011135857461024499;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Improvement in neutralization capability of all 4 convalescent sera tested.;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22894	22894	.	+	.	ID=ID_63;Name=K444N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=444;ao=5;dp=449;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G1332T;aa_name=p.K444N;hgvs_nt=NC_045512.2:g.1332G>T;hgvs_aa=YP_009724390.1:p.Lys444Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011135857461024499;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;citation=Weisblum et al. (2020);comb_mutation=;function_description=Positive selection (up to 14% of supernatant sequences) after COV-NY convalescent plasma assay;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1.full.pdf;citation=Motozono et al. (2021);comb_mutation=;function_description=L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_65;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442760v1;citation=Yadav et al. (2021);comb_mutation=E484Q,P681R;function_description=Gross examination of 3+3 hamster lung specimens showed pronounced congestion and hemorrhages on days 5 and 7 post-infection in the case of the B.1.617.1 as compared with the B.1. The lung lesions with  the B.1 variant were minimal to mild whereas with B.1.617.1 they were moderate. For B.1 pneumonic changes were minimal to mild (inflammatory cell infiltration, focal consolidation and mild congestion). The pronounced changes (moderate to severe) with mononuclear infiltration in the alveolar interstitial space, interstitial septal thickening, consolidation and pneumocyte hyperplasia were observed with B.1.617.1 variant consistently.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771;citation=Li et al. (2020);comb_mutation=;function_description=Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_66;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_67;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E484Q,D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617) showed a 1.85x increase  in binding (KD) relative to D614G. [exact variant list not provided in manuscript, is inferred fro common knowledge];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	"ID=ID_60;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=G142D,E154K,E484Q,D614G,P681R,Q1071H;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as ""not significant"". [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=~1.7-fold increase in binding affinity vs wild type.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_60;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=G142D,E154K,E484Q,D614G,P681R,Q1071H;function_description=~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistucally significant, but error bars say otherwise in Figure 4];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=;function_description=We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_65;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442760v1;citation=Yadav et al. (2021);comb_mutation=E484Q,P681R;function_description=In 9 infected hamsters each for B.1 and B.1.617.1, no significant change in viral load or subgenomic RNA levels were detected.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_60;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=G142D,E154K,E484Q,D614G,P681R,Q1071H;function_description=Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_66;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_67;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=E484Q,D614G;function_description=Pseudotyped viruses for B.1.617 was 2.3-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=;function_description=Observed ~2x decrease on average in 16 health workers' convalescent sera.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_68;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=E484Q,P681R,D614G;function_description=Normalized for particle number, on ACE2.293T cells showed that the B.1.617 spike protein was >2-fold increase in infectivity relative to D614G wild type.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_66;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_67;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=E484Q,D614G;function_description=The combination caused a 3-fold increase in infectivity relative to D614G wild type. [compare to 3.5x for L452R alone];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_66;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_67;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E484Q,D614G;function_description=This variant combination (representing lineage B.1.617) showed a 1.22x decrease in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred fro common knowledge];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_60;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=G142D,E154K,E484Q,D614G,P681R,Q1071H;function_description=Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_66;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_67;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=E484Q,D614G;function_description=Pseudotyped viruses for B.1.617 was 4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 5-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_67;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E484Q,D614G;function_description=1.4x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	"ID=ID_58;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=T95I,G142D,E154K,E484Q,D614G,P681R,Q1071H;function_description=Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_60;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=G142D,E154K,E484Q,D614G,P681R,Q1071H;function_description=Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_60;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=G142D,E154K,E484Q,D614G,P681R,Q1071H;function_description=1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_69;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=E484Q;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484Q had a ~5x drop in neutralization (vs ~10x for E484K). When E484Q and L452R were combined, the fold change was significant, but similar to that of L452R alone (~2x), suggesting no evidence for an additive effect [perhaps even E484Q effect dilution].;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_60;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.23.441101v1;citation=Yadav et al. (2021);comb_mutation=G142D,E154K,E484Q,D614G,P681R,Q1071H;function_description=Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.32 fold;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_64;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_66;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_67;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=450;dp=450;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E484Q,D614G;function_description=This variant combination (representing lineage B.1.617) showed a 1.30x decrease in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.18x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. [exact variant list not provided in manuscript, is inferred fro common knowledge];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_65;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442760v1;citation=Yadav et al. (2021);comb_mutation=L452R,P681R;function_description=Gross examination of 3+3 hamster lung specimens showed pronounced congestion and hemorrhages on days 5 and 7 post-infection in the case of the B.1.617.1 as compared with the B.1. The lung lesions with  the B.1 variant were minimal to mild whereas with B.1.617.1 they were moderate. For B.1 pneumonic changes were minimal to mild (inflammatory cell infiltration, focal consolidation and mild congestion). The pronounced changes (moderate to severe) with mononuclear infiltration in the alveolar interstitial space, interstitial septal thickening, consolidation and pneumocyte hyperplasia were observed with B.1.617.1 variant consistently.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_70;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=>20% (ELISA significance threshold) drop in antibody binding by this variant against monoclonal antibody VH-Fc ab8.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_67;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R,D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617) showed a 1.85x increase  in binding (KD) relative to D614G. [exact variant list not provided in manuscript, is inferred fro common knowledge];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_60;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=G142D,E154K,L452R,D614G,P681R,Q1071H;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as ""not significant"". [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_60;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=G142D,E154K,L452R,D614G,P681R,Q1071H;function_description=~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_70;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a 10x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_65;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442760v1;citation=Yadav et al. (2021);comb_mutation=L452R,P681R;function_description=In 9 infected hamsters each for B.1 and B.1.617.1, no significant change in viral load or subgenomic RNA levels were detected.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_70;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~20x binding against this isolated mutation. Casirivimab lost ~4x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_60;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=G142D,E154K,L452R,D614G,P681R,Q1071H;function_description=Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_67;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=L452R,D614G;function_description=Pseudotyped viruses for B.1.617 was 2.3-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_70;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.02.003;citation=Greaney et al. (2021);comb_mutation=;function_description=In 3 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD,  E484Q shows a notably resistant profile, comparable to or even more resistant than E484K at  later time points (i.e. more resistant to immune cell somatic mutation evolution), see Figure 5a,b. Subject C 32 days post-infection showed >>10 fold reduction in neutralization, reducing to ~10-fold by day 104. Subject B 26 days post-infection showed ~10 fold reduction in neutralization, reducing to ~4x at day 113. Notably, Subject B also showed smaller than typical (~10 vs 30+ fold) reduction in one-month neutralization by E484K at day 32,  and no E484K immune escape at day 104. Subject I 26 days post-infection showed ~10 fold reduction in neutralization, with no reduction in escape at day 102. Notably, Subject I also showed smaller than typical (~10 vs 30+ fold) reduction in one-month neutralization by E484K at day 26,  and no E484K immune escape at day 102.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_68;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=L452R,P681R,D614G;function_description=Normalized for particle number, on ACE2.293T cells showed that the B.1.617 spike protein was >2-fold increase in infectivity relative to D614G wild type.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_67;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=L452R,D614G;function_description=The combination caused a 3-fold increase in infectivity relative to D614G wild type. [compare to 3.5x for L452R alone];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_67;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R,D614G;function_description=This variant combination (representing lineage B.1.617) showed a 1.22x decrease in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred fro common knowledge];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_60;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=G142D,E154K,L452R,D614G,P681R,Q1071H;function_description=Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_67;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=L452R,D614G;function_description=Pseudotyped viruses for B.1.617 was 4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 5-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_67;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R,D614G;function_description=1.4x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_58;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=T95I,G142D,E154K,L452R,D614G,P681R,Q1071H;function_description=Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_60;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=G142D,E154K,L452R,D614G,P681R,Q1071H;function_description=Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_60;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=G142D,E154K,L452R,D614G,P681R,Q1071H;function_description=1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_69;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=L452R;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484Q had a ~5x drop in neutralization (vs ~10x for E484K). When E484Q and L452R were combined, the fold change was significant, but similar to that of L452R alone (~2x), suggesting no evidence for an additive effect [perhaps even E484Q effect dilution].;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_60;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.23.441101v1;citation=Yadav et al. (2021);comb_mutation=G142D,E154K,L452R,D614G,P681R,Q1071H;function_description=Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_70;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_67;Name=E484Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G1450C;aa_name=p.E484Q;hgvs_nt=NC_045512.2:g.1450G>C;hgvs_aa=YP_009724390.1:p.Glu484Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R,D614G;function_description=This variant combination (representing lineage B.1.617) showed a 1.30x decrease in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.18x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. [exact variant list not provided in manuscript, is inferred fro common knowledge];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1;citation=Landis et al. (2021);comb_mutation=;function_description=Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_57;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T95I;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_66;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_67;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R,E484Q;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617) showed a 1.85x increase  in binding (KD) relative to D614G. [exact variant list not provided in manuscript, is inferred fro common knowledge];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_60;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,P681R,Q1071H;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as ""not significant"". [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_60;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,P681R,Q1071H;function_description=~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_72;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=P681R;function_description=Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1;citation=Barrett et al. (2021);comb_mutation=;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et l. (2020);comb_mutation=;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/elife.65365;citation=Daniloski et al. (2021);comb_mutation=;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.nature.com/articles/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_60;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,P681R,Q1071H;function_description=Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_66;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_67;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=L452R,E484Q;function_description=Pseudotyped viruses for B.1.617 was 2.3-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_68;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=L452R,E484Q,P681R;function_description=Normalized for particle number, on ACE2.293T cells showed that the B.1.617 spike protein was >2-fold increase in infectivity relative to D614G wild type.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_66;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=L452R;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_67;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=L452R,E484Q;function_description=The combination caused a 3-fold increase in infectivity relative to D614G wild type. [compare to 3.5x for L452R alone];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_57;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T95I;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_66;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_67;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R,E484Q;function_description=This variant combination (representing lineage B.1.617) showed a 1.22x decrease in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred fro common knowledge];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_60;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,P681R,Q1071H;function_description=Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_66;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_67;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=L452R,E484Q;function_description=Pseudotyped viruses for B.1.617 was 4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 5-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_67;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R,E484Q;function_description=1.4x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_58;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=T95I,G142D,E154K,L452R,E484Q,P681R,Q1071H;function_description=Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_60;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,P681R,Q1071H;function_description=Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_60;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,P681R,Q1071H;function_description=1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_60;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.23.441101v1;citation=Yadav et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,P681R,Q1071H;function_description=Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/;citation=Yurkovetskiy et al. (2020);comb_mutation=;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2;citation=Weissman et al. (2020);comb_mutation=;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_57;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T95I;function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_66;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_67;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R,E484Q;function_description=This variant combination (representing lineage B.1.617) showed a 1.30x decrease in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.18x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. [exact variant list not provided in manuscript, is inferred fro common knowledge];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_65;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442760v1;citation=Yadav et al. (2021);comb_mutation=L452R,E484Q;function_description=Gross examination of 3+3 hamster lung specimens showed pronounced congestion and hemorrhages on days 5 and 7 post-infection in the case of the B.1.617.1 as compared with the B.1. The lung lesions with  the B.1 variant were minimal to mild whereas with B.1.617.1 they were moderate. For B.1 pneumonic changes were minimal to mild (inflammatory cell infiltration, focal consolidation and mild congestion). The pronounced changes (moderate to severe) with mononuclear infiltration in the alveolar interstitial space, interstitial septal thickening, consolidation and pneumocyte hyperplasia were observed with B.1.617.1 variant consistently.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	"ID=ID_60;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,D614G,Q1071H;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as ""not significant"". [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_60;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,D614G,Q1071H;function_description=~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_72;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_73;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication;citation=Maaroufi (2021);comb_mutation=;function_description=This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry). [Inference from similar positively charged substitution P681H actually described in the work];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_65;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442760v1;citation=Yadav et al. (2021);comb_mutation=L452R,E484Q;function_description=In 9 infected hamsters each for B.1 and B.1.617.1, no significant change in viral load or subgenomic RNA levels were detected.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_60;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,D614G,Q1071H;function_description=Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_68;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=L452R,E484Q,D614G;function_description=Normalized for particle number, on ACE2.293T cells showed that the B.1.617 spike protein was >2-fold increase in infectivity relative to D614G wild type.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_60;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,D614G,Q1071H;function_description=Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	"ID=ID_58;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=T95I,G142D,E154K,L452R,E484Q,D614G,Q1071H;function_description=Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_60;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,D614G,Q1071H;function_description=Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_60;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,D614G,Q1071H;function_description=1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_60;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.23.441101v1;citation=Yadav et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,D614G,Q1071H;function_description=Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_73;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=449;dp=449;sample_size=472;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing. [PG: Inferred by conservative AA substitution of described P681H];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24406	24406	.	+	.	ID=ID_74;Name=L948L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=439;ao=9;dp=448;sample_size=472;Reference_seq=T;Variant_seq=C;nt_name=g.T2844C;aa_name=p.L948L;hgvs_nt=NC_045512.2:g.2844T>C;hgvs_aa=YP_009724390.1:p.Leu948Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.020089285714285716;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24475	24475	.	+	.	ID=ID_75;Name=G971G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=439;ao=9;dp=448;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T2913G;aa_name=p.G971G;hgvs_nt=NC_045512.2:g.2913T>G;hgvs_aa=YP_009724390.1:p.Gly971Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.020089285714285716;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24775	24775	.	+	.	"ID=ID_60;Name=Q1071H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=T;nt_name=g.A3213T;aa_name=p.Q1071H;hgvs_nt=NC_045512.2:g.3213A>T;hgvs_aa=YP_009724390.1:p.Gln1071His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,D614G,P681R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as ""not significant"". [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	24775	24775	.	+	.	ID=ID_60;Name=Q1071H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=T;nt_name=g.A3213T;aa_name=p.Q1071H;hgvs_nt=NC_045512.2:g.3213A>T;hgvs_aa=YP_009724390.1:p.Gln1071His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,D614G,P681R;function_description=~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24775	24775	.	+	.	ID=ID_60;Name=Q1071H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=T;nt_name=g.A3213T;aa_name=p.Q1071H;hgvs_nt=NC_045512.2:g.3213A>T;hgvs_aa=YP_009724390.1:p.Gln1071His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,D614G,P681R;function_description=Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24775	24775	.	+	.	ID=ID_60;Name=Q1071H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=T;nt_name=g.A3213T;aa_name=p.Q1071H;hgvs_nt=NC_045512.2:g.3213A>T;hgvs_aa=YP_009724390.1:p.Gln1071His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,D614G,P681R;function_description=Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24775	24775	.	+	.	"ID=ID_58;Name=Q1071H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=T;nt_name=g.A3213T;aa_name=p.Q1071H;hgvs_nt=NC_045512.2:g.3213A>T;hgvs_aa=YP_009724390.1:p.Gln1071His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=T95I,G142D,E154K,L452R,E484Q,D614G,P681R;function_description=Neutralization efficiency (ID50) against B.1.617.1-v1 (""Kappa"") reduced 3.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	24775	24775	.	+	.	ID=ID_60;Name=Q1071H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=T;nt_name=g.A3213T;aa_name=p.Q1071H;hgvs_nt=NC_045512.2:g.3213A>T;hgvs_aa=YP_009724390.1:p.Gln1071His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,D614G,P681R;function_description=Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24775	24775	.	+	.	ID=ID_60;Name=Q1071H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=T;nt_name=g.A3213T;aa_name=p.Q1071H;hgvs_nt=NC_045512.2:g.3213A>T;hgvs_aa=YP_009724390.1:p.Gln1071His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,D614G,P681R;function_description=1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript];heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24775	24775	.	+	.	ID=ID_60;Name=Q1071H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=A;Variant_seq=T;nt_name=g.A3213T;aa_name=p.Q1071H;hgvs_nt=NC_045512.2:g.3213A>T;hgvs_aa=YP_009724390.1:p.Gln1071His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.23.441101v1;citation=Yadav et al. (2021);comb_mutation=G142D,E154K,L452R,E484Q,D614G,P681R;function_description=Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.  Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25352	25352	.	+	.	ID=ID_76;Name=V1264L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G3790T;aa_name=p.V1264L;hgvs_nt=NC_045512.2:g.3790G>T;hgvs_aa=YP_009724390.1:p.Val1264Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25469	25469	.	+	.	ID=ID_77;Name=S26L;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C77T;aa_name=p.S26L;hgvs_nt=NC_045512.2:g.77C>T;hgvs_aa=YP_009724391.1:p.Ser26Leu;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25494	25494	.	+	.	ID=ID_78;Name=T34T;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G102T;aa_name=p.T34T;hgvs_nt=NC_045512.2:g.102G>T;hgvs_aa=YP_009724391.1:p.Thr34Thr;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25552	25552	.	+	.	ID=ID_79;Name=A54S;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G160T;aa_name=p.A54S;hgvs_nt=NC_045512.2:g.160G>T;hgvs_aa=YP_009724391.1:p.Ala54Ser;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25714	25714	.	+	.	ID=ID_80;Name=L108F;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=447;ao=4;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C322T;aa_name=p.L108F;hgvs_nt=NC_045512.2:g.322C>T;hgvs_aa=YP_009724391.1:p.Leu108Phe;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008869179600886918;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26071	26071	.	+	.	ID=ID_81;Name=H227Y;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C679T;aa_name=p.H227Y;hgvs_nt=NC_045512.2:g.679C>T;hgvs_aa=YP_009724391.1:p.His227Tyr;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26447	26447	.	+	.	ID=ID_82;Name=S68F;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=446;ao=5;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C203T;aa_name=p.S68F;hgvs_nt=NC_045512.2:g.203C>T;hgvs_aa=YP_009724392.1:p.Ser68Phe;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011086474501108648;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26681	26681	.	+	.	ID=ID_83;Name=F53F;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C159T;aa_name=p.F53F;hgvs_nt=NC_045512.2:g.159C>T;hgvs_aa=YP_009724393.1:p.Phe53Phe;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26741	26741	.	+	.	ID=ID_84;Name=I73I;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=A;Variant_seq=T;nt_name=g.A219T;aa_name=p.I73I;hgvs_nt=NC_045512.2:g.219A>T;hgvs_aa=YP_009724393.1:p.Ile73Ile;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26767	26767	.	+	.	ID=ID_85;Name=I82S;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=T;Variant_seq=G;nt_name=g.T245G;aa_name=p.I82S;hgvs_nt=NC_045512.2:g.245T>G;hgvs_aa=YP_009724393.1:p.Ile82Ser;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27260	27260	.	+	.	ID=ID_86;Name=R20K;alias=n/a;gene=ORF6;protein_name=ORF6 protein;protein_symbol=ORF6;protein_id=YP_009724394.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=448;ao=3;dp=451;sample_size=472;Reference_seq=G;Variant_seq=A;nt_name=g.G59A;aa_name=p.R20K;hgvs_nt=NC_045512.2:g.59G>A;hgvs_aa=YP_009724394.1:p.Arg20Lys;hgvs_alias=n/a;vcf_gene=ORF6;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066518847006651885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27520	27520	.	+	.	ID=ID_87;Name=N43Y;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=85;ao=360;dp=445;sample_size=472;Reference_seq=A;Variant_seq=T;nt_name=g.A127T;aa_name=p.N43Y;hgvs_nt=NC_045512.2:g.127A>T;hgvs_aa=YP_009724395.1:p.Asn43Tyr;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8089887640449438;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27638	27638	.	+	.	ID=ID_88;Name=V82A;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=444;dp=444;sample_size=472;Reference_seq=T;Variant_seq=C;nt_name=g.T245C;aa_name=p.V82A;hgvs_nt=NC_045512.2:g.245T>C;hgvs_aa=YP_009724395.1:p.Val82Ala;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27643	27643	.	+	.	ID=ID_89;Name=P84S;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=439;ao=5;dp=444;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C250T;aa_name=p.P84S;hgvs_nt=NC_045512.2:g.250C>T;hgvs_aa=YP_009724395.1:p.Pro84Ser;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01126126126126126;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27691	27691	.	+	.	ID=ID_90;Name=I100F;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=443;ao=7;dp=450;sample_size=472;Reference_seq=A;Variant_seq=T;nt_name=g.A298T;aa_name=p.I100F;hgvs_nt=NC_045512.2:g.298A>T;hgvs_aa=YP_009724395.1:p.Ile100Phe;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.015555555555555555;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27957	27957	.	+	.	ID=ID_91;Name=L22I;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=442;ao=5;dp=447;sample_size=472;Reference_seq=T;Variant_seq=A;nt_name=g.T64A;aa_name=p.L22I;hgvs_nt=NC_045512.2:g.64T>A;hgvs_aa=YP_009724396.1:p.Leu22Ile;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011185682326621925;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28044	28044	.	+	.	ID=ID_92;Name=A51S;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=440;ao=3;dp=443;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G151T;aa_name=p.A51S;hgvs_nt=NC_045512.2:g.151G>T;hgvs_aa=YP_009724396.1:p.Ala51Ser;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006772009029345372;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	complex	28251	28251	.	+	.	ID=ID_93;Name=FI120VL;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=424;ao=19;dp=447;sample_size=472;Reference_seq=TTCA;Variant_seq=GTTC;nt_name=g.TTCA358_361GTTC;aa_name=p.FI120VL;hgvs_nt=n/a;hgvs_aa=YP_009724396.1:p.PheIle120ValLeu;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.042505592841163314;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28251	28251	.	+	.	ID=ID_94;Name=F120F;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=424;ao=4;dp=447;sample_size=472;Reference_seq=TTCA;Variant_seq=TTTA;nt_name=g.C360T;aa_name=p.F120F;hgvs_nt=NC_045512.2:g.360C>T;hgvs_aa=YP_009724396.1:p.Phe120Phe;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=SILENT;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008948545861297539;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	28270	28270	.	+	.	ID=ID_95;Name=g.-3delA;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=446;dp=446;sample_size=472;Reference_seq=TA;Variant_seq=T;nt_name=g.-3delA;aa_name=;hgvs_nt=NC_045512.2:g.-3del;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28655	28655	.	+	.	ID=ID_96;Name=D128Y;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=445;ao=4;dp=449;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G382T;aa_name=p.D128Y;hgvs_nt=NC_045512.2:g.382G>T;hgvs_aa=YP_009724397.2:p.Asp128Tyr;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008908685968819599;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28703	28703	.	+	.	ID=ID_97;Name=D144H;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=437;ao=14;dp=451;sample_size=472;Reference_seq=G;Variant_seq=C;nt_name=g.G430C;aa_name=p.D144H;hgvs_nt=NC_045512.2:g.430G>C;hgvs_aa=YP_009724397.2:p.Asp144His;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.031042128603104215;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28754	28754	.	+	.	ID=ID_98;Name=L161F;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=444;ao=7;dp=451;sample_size=472;Reference_seq=C;Variant_seq=T;nt_name=g.C481T;aa_name=p.L161F;hgvs_nt=NC_045512.2:g.481C>T;hgvs_aa=YP_009724397.2:p.Leu161Phe;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.015521064301552107;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28881	28881	.	+	.	ID=ID_99;Name=R203M;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=451;dp=451;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G608T;aa_name=p.R203M;hgvs_nt=NC_045512.2:g.608G>T;hgvs_aa=YP_009724397.2:p.Arg203Met;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=RNA binding;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455082v1;citation=Syed et al. (2021);comb_mutation=;function_description=Northern blot analysis of novel mutant virus-like-particles (VLPs) shows most increase in RNA content of any N mutation tested, suggesting that this mutation improves virus particle production (requisite RNA packaging signal binding site in nsp15/16 boundary is included in the VLP).;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29402	29402	.	+	.	ID=ID_100;Name=D377Y;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=448;dp=448;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G1129T;aa_name=p.D377Y;hgvs_nt=NC_045512.2:g.1129G>T;hgvs_aa=YP_009724397.2:p.Asp377Tyr;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29642	29642	.	+	.	ID=ID_101;Name=Q29E;alias=n/a;gene=ORF10;protein_name=ORF10 protein;protein_symbol=ORF10;protein_id=YP_009725255.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=443;ao=6;dp=449;sample_size=472;Reference_seq=C;Variant_seq=G;nt_name=g.C85G;aa_name=p.Q29E;hgvs_nt=NC_045512.2:g.85C>G;hgvs_aa=YP_009725255.1:p.Gln29Glu;hgvs_alias=n/a;vcf_gene=ORF10;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013363028953229399;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29648	29648	.	+	.	ID=ID_102;Name=D31Y;alias=n/a;gene=ORF10;protein_name=ORF10 protein;protein_symbol=ORF10;protein_id=YP_009725255.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=446;ao=3;dp=449;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G91T;aa_name=p.D31Y;hgvs_nt=NC_045512.2:g.91G>T;hgvs_aa=YP_009725255.1:p.Asp31Tyr;hgvs_alias=n/a;vcf_gene=ORF10;mutation_type=MISSENSE;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066815144766146995;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29700	29700	.	+	.	ID=ID_103;Name=g.A29700G;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=444;ao=5;dp=449;sample_size=472;Reference_seq=A;Variant_seq=G;nt_name=g.A29700G;aa_name=;hgvs_nt=NC_045512.2:g.29700A>G;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011135857461024499;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29742	29742	.	+	.	ID=ID_104;Name=g.G29742T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=443;dp=443;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G29742T;aa_name=;hgvs_nt=NC_045512.2:g.29742G>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29774	29774	.	+	.	ID=ID_105;Name=g.C29774G;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=39;ao=1;dp=40;sample_size=472;Reference_seq=C;Variant_seq=G;nt_name=g.C29774G;aa_name=;hgvs_nt=NC_045512.2:g.29774C>G;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29781	29781	.	+	.	ID=ID_106;Name=g.G29781T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=34;ao=6;dp=40;sample_size=472;Reference_seq=G;Variant_seq=T;nt_name=g.G29781T;aa_name=;hgvs_nt=NC_045512.2:g.29781G>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.617.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.15;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Kappa;variant_type=VOI;voi_designation_date=04-Apr-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
